Pharma BD Deal Intelligence
Gilead and Goldfinch Bio enter $2 billion-plus partnership to develop kidney disease drugs leveraging Goldfinch Kidney Genome Atlas technology platform.
Startup Goldfinch Bio signs $109 million upfront deal with Gilead to develop treatments for kidney disease, with total potential value exceeding $2 billion.
Karuna Therapeutics announces exclusive global license to Goldfinch Bio's TRPC4/5 candidates (incl GFB-887) from the Goldfinch assignment estate (Feb 2,…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Gilead partnered with Goldfinch Bio to develop kidney disease therapies, paying $55M upfront plus $54M in research funding with up to $2B in milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Goldfinch Bio Inc. (this deal) | 2019 | $240M | 26 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2019 deals · Gilead Sciences Inc. deals · Nephrology deals